Effects of lead administration at low doses by different routes on rat spleens. Study of response of splenic lymphocytes and tissue lysozyme.
The aim of this study was to evaluate the effects of low doses of lead (200 ppm of PbAc(2) for 4 weeks) on rat spleens using different routes of administration. The study has been carried out at different levels: a histological evaluation has been made, and alterations of cell proliferation, B and T lymphocyte subpopulations, and CD4(+) and CD8(+) T cell subpopulations have been evaluated. Apoptosis and necrosis of lymphoid cells were also analysed. Furthermore, lysozyme activity was measured. Results indicate a large increase in spleen size when lead is administered by intraperitoneal injection, being this route in which lead causes larger modifications in all of the parameters measured. Lead administered orally causes histological modifications, such as an increase in the number of lymphocytes as well as edema. However, significant alterations in other parameters studied have not been detected. Lead administration by intraperitoneal route causes more evident histological modifications as well as an increase in the number of lymphocytes, and also induces a decrease in the percentage of B(+), T(+) and CD4(+) cells, and an increase in CD8(+) cells. Cell death of splenic lymphocytes is not altered by lead. With regard to the immune innate response, lead behaves as an immunomodulator as can be deduced from data on lysozyme activity in tissue. Therefore, it is possible to affirm that the effect of low doses of lead depends on the route of administration. Thus, the intraperitoneal route, through which lead goes directly to the bloodstream, causes drastic effects, generating important immunological alterations.
Teijón
César
C
Departamento de Bioquímica y Biología Molecular III, Facultad de Medicina, Universidad Complutense de Madrid, 28040, Madrid, Spain. jmt77255@med.ucm.es
Olmo
Rosa
R
Dolores Blanco
María
M
Romero
Arturo
A
María Teijón
Jose
J
D000284:Administration, Oral; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D002452:Cell Count; D005434:Flow Cytometry; D006651:Histocytochemistry; D007274:Injections, Intraperitoneal; D007854:Lead / Q000008:administration & dosage / Q000633:toxicity*; D016131:Lymphocyte Subsets / Q000187:drug effects*; D008297:Male; D009113:Muramidase / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology
D007854:Lead; D009113:Muramidase